Editas Medicine (EDIT) Tops Q3 EPS by 25c; Cash and Cash Equivalents of $657.0M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Editas Medicine Announces Third Quarter 2021 Results and Business Updates
November 8, 2021 7:00 AM ESTEDIT-101 Phase 1/2 BRILLIANCE trial initial clinical data demonstrated favorable safety profile and preliminary evidence of clinical benefit; enrollment ongoing in adult high-dose and pediatric mid-dose cohorts
EDIT-301 Phase 1/2 RUBY trial for the treatment of sickle cell disease currently enrolling study participants
Presented preclinical data on novel SLEEK gene editing technology enabling high efficiency, multi-transgene knock-in in multiple clinically relevant cell types
CAMBRIDGE, Mass., , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported... More
